Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 5
1995 6
1996 5
1997 7
1998 4
1999 14
2000 6
2001 4
2002 6
2003 3
2005 12
2006 8
2007 25
2008 14
2009 11
2010 12
2011 17
2012 9
2013 9
2014 5
2015 5
2016 5
2017 5
2018 2
2019 3
2020 2
2021 1
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

195 results

Results by year

Filters applied: . Clear all
Page 1
Satraplatin: leading the new generation of oral platinum agents.
Bhargava A, Vaishampayan UN. Bhargava A, et al. Expert Opin Investig Drugs. 2009 Nov;18(11):1787-97. doi: 10.1517/13543780903362437. Expert Opin Investig Drugs. 2009. PMID: 19888874 Free PMC article. Review.
Since satraplatin is more hydrophobic than cisplatin or oxaliplatin, it appears to demonstrate efficacy in cisplatin-resistant cell lines. ...METHODS: A literature review was conducted in the MEDLINE database from 1985 to present using the keywords 'satraplatin' or …
Since satraplatin is more hydrophobic than cisplatin or oxaliplatin, it appears to demonstrate efficacy in cisplatin-resistant cell l …
Satraplatin for the therapy of castration-resistant prostate cancer.
Sonpavde G, Sternberg CN. Sonpavde G, et al. Future Oncol. 2009 Sep;5(7):931-40. doi: 10.2217/fon.09.84. Future Oncol. 2009. PMID: 19792961 Review.
Satraplatin did not significantly extend survival, although this analysis may have been confounded by post-study therapy. Further development is ongoing with the evaluation of combination regimens containing satraplatin in other solid tumors. In addition, efforts ar …
Satraplatin did not significantly extend survival, although this analysis may have been confounded by post-study therapy. Further dev …
Satraplatin Demonstrates High Cytotoxic Activity Against Genetically Defined Lymphoid Malignancies.
Zander T, Xue J, Markson G, Dahm F, Renner C. Zander T, et al. Anticancer Res. 2022 Apr;42(4):1821-1832. doi: 10.21873/anticanres.15658. Anticancer Res. 2022. PMID: 35347000
Hence, we carried out a systematic biomarker analysis to identify hematological malignancies with high susceptibility to satraplatin. MATERIALS AND METHODS: Half-maximal inhibitory concentrations (IC(50)) for satraplatin and cisplatin were determined for 66 differen …
Hence, we carried out a systematic biomarker analysis to identify hematological malignancies with high susceptibility to satraplatin. …
Satraplatin: an orally available platinum analog for the treatment of cancer.
Choy H. Choy H. Expert Rev Anticancer Ther. 2006 Jul;6(7):973-82. doi: 10.1586/14737140.6.7.973. Expert Rev Anticancer Ther. 2006. PMID: 16831070 Review.
Satraplatin is a novel, orally bioavailable, platinum anticancer drug. ...Positive results from this trial would support regulatory approval for satraplatin for this indication. The availability of an active oral platinum agent, such as satraplatin, with few …
Satraplatin is a novel, orally bioavailable, platinum anticancer drug. ...Positive results from this trial would support regulatory a …
Clinical and pharmacokinetic evaluation of satraplatin.
Doshi G, Sonpavde G, Sternberg CN. Doshi G, et al. Expert Opin Drug Metab Toxicol. 2012 Jan;8(1):103-11. doi: 10.1517/17425255.2012.636352. Epub 2011 Nov 19. Expert Opin Drug Metab Toxicol. 2012. PMID: 22098065 Review.
AREAS COVERED: The clinical activity of satraplatin in metastatic castrate-resistant prostate cancer (mCRPC), breast, lung and other advanced solid tumors is discussed with a focus on its pharmacokinetic properties. ...Despite the activity of satraplatin in mCRPC, s …
AREAS COVERED: The clinical activity of satraplatin in metastatic castrate-resistant prostate cancer (mCRPC), breast, lung and other …
Satraplatin. BMS 182751, BMY 45594, JM 216.
[No authors listed] [No authors listed] Drugs R D. 2002;3(1):67-71. doi: 10.2165/00126839-200203010-00017. Drugs R D. 2002. PMID: 11881537 Review. No abstract available.
Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation.
McKeage MJ. McKeage MJ. Drugs. 2007;67(6):859-69. doi: 10.2165/00003495-200767060-00003. Drugs. 2007. PMID: 17428104 Review.
Satraplatin is the first orally administered platinum drug to be evaluated in the clinic. ...In >600 treated patients, satraplatin was generally well tolerated and the most common adverse event was non-cumulative myelosuppression....
Satraplatin is the first orally administered platinum drug to be evaluated in the clinic. ...In >600 treated patients, satrapla …
The resurgence of platinum-based cancer chemotherapy.
Kelland L. Kelland L. Nat Rev Cancer. 2007 Aug;7(8):573-84. doi: 10.1038/nrc2167. Epub 2007 Jul 12. Nat Rev Cancer. 2007. PMID: 17625587 Review.
Key developments include the elucidation of mechanisms of tumour resistance to these drugs, the introduction of new platinum-based agents (oxaliplatin, satraplatin and picoplatin), and clinical combination studies using platinum drugs with resistance modulators or new mole …
Key developments include the elucidation of mechanisms of tumour resistance to these drugs, the introduction of new platinum-based agents (o …
Satraplatin: BMS 182751, BMY 45594, JM 216.
[No authors listed] [No authors listed] Drugs R D. 2007;8(2):125-32. doi: 10.2165/00126839-200708020-00008. Drugs R D. 2007. PMID: 17324011 Review.
This global, multicentre, randomised study, called SPARC (Satraplatin and Prednisone Against Refractory Cancer), is assessing satraplatin plus prednisone versus prednisone alone as second-line therapy in HRPC patients. ...However, the company closed all ongoing tria …
This global, multicentre, randomised study, called SPARC (Satraplatin and Prednisone Against Refractory Cancer), is assessing satr …
Current status and future prospects for satraplatin, an oral platinum analogue.
Choy H, Park C, Yao M. Choy H, et al. Clin Cancer Res. 2008 Mar 15;14(6):1633-8. doi: 10.1158/1078-0432.CCR-07-2176. Clin Cancer Res. 2008. PMID: 18347164 Review.
Satraplatin and its major metabolite, JM118, have shown antineoplastic activity in in vitro, in vivo, and in clinical settings. ...The most mature clinical data for satraplatin come from the recently completed phase III trial that investigated the efficacy of sat …
Satraplatin and its major metabolite, JM118, have shown antineoplastic activity in in vitro, in vivo, and in clinical settings. ...Th …
195 results